ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Articles tagged "Calcineurin"

  • 2020 American Transplant Congress

    MTOR-Inhibitor Regimens and Malignancy after Kidney Transplantation: Can the Risk Be Modified by Considering Human Leukocyte Antigen (HLA) Mismatch in Immunosuppression Selection?

    A. Santos1, C. Chen1, K. Alquadan2, M. A. Leghrouz2, X. Wen3

    1University of Florida, Gainesville, FL, 2Division of Nephrology, Hypertension, & Renal Transplantation, University of Florida, Gainesville, FL, 3Department of Pharmacy Practice, University of Rhode Island, Kingston, RI

    *Purpose: We investigated the outcomes of mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs) in categories of donor/recipient pre-transplant…
  • 2020 American Transplant Congress

    Steroids Ameriplate the Progression of Calcineurin Inhibitors Nephrotoxicity in Kidney Allografts

    N. Iwahara1, H. Sasaki2, D. Iwami1, K. Hotta1, Y. Takada1, H. Higuchi2, T. Tanabe2, N. Shinohara1

    1Hokkaido University, Sapporo, Japan, 2Sapporo City General Hospital, Sapporo, Japan

    *Purpose: Although calcineurin inhibitors (CNI) lead to excellent short-term kidney allograft outcome, chronic nephrotoxicity is a major concern which affects long-term allograft survival. It has…
  • 2020 American Transplant Congress

    Impact of CYP3A5 Phenotype on Early Time in Therapeutic Range among Pediatric Renal and Heart Transplant Recipients

    A. Leino, A. Pasternak

    University of Michigan, Ann Arbor, MI

    *Purpose: Tacrolimus time in therapeutic range (TTR) as a measure of intra-patient variability has been associated with poor long-term outcomes. Multiple factors may contribute to…
  • 2020 American Transplant Congress

    Impact of a Pharmacist Led Outpatient Tacrolimus Monitoring Protocol in Renal Transplant Recipients

    K. L. Owen, M. Palettas, H. Winters, T. E. Pesavento, A. Rajab, O. Witkowsky

    Ohio State University Wexner Medical Center, Columbus, OH

    *Purpose: The purpose of this study is to compare the time within therapeutic range (TTR) of tacrolimus (TAC) before and after the initiation of a…
  • 2020 American Transplant Congress

    Comparing Weight-Based Dosing of Envarsus XR in Obese and Non-Obese Renal Transplant Recipients

    N. Breslin, N. Jandovitz, V. Nair, M. Abate, L. Teperman

    North Shore University Hospital, Manhasset, NY

    *Purpose: Tacrolimus has a narrow therapeutic window and significant inter- and intra-patient variability leading to variations in drug concentration. The recommended initial weight-based dose of…
  • 2020 American Transplant Congress

    Impact of Concentrations on Conversion from Twice‑Daily to Once‑Daily Tacrolimus in Stable Kidney Graft Recipients: A Single-Center Retrospective Study

    Z. Wang, Y. Cao, Y. Fu

    Transplant Surgery, Tianjin First Central Hospital, Tian Jin, China

    *Purpose: Potential benefits of once-daily tacrolimus include improved adherence to immunosuppressives and decreased Intrapatient variability (IPV) post kidney transplantation. A retrospective analysis was performed to…
  • 2020 American Transplant Congress

    Pharmacokinetic Evaluation of a De Novo Envarsus XR® (tacrolimus Extended Release) Dosing Strategy in Kidney Transplant Recipients

    J. Schulte1, C. Kane1, K. Cunningham1, C. D'Agostino1, M. Kapugi1, A. Novak1, A. Shetty2, J. Leventhal2, J. Friedewald2

    1Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, 2Division of Transplantation, Northwestern Memorial Hospital, Chicago, IL

    *Purpose: Envarsus XR® is a once-daily tablet formulation of tacrolimus recently approved for the prophylaxis of organ rejection in de novo kidney transplant recipients (KTx).…
  • 2020 American Transplant Congress

    Sodium Zirconium Cyclosilicate Use in Solid Organ Transplant Recipients and its Effect on Potassium and Immunosuppression

    R. Winstead, M. Demehin, I. Yakubu, C. Song, A. Brown, M. Levy, L. Kamal, G. Gupta

    VCU Health, Richmond, VA

    *Purpose: Transplant recipients often suffer from hyperkalemia which can limit pharmacotherapy. The cause of hyperkalemia is often multifactorial including kidney dysfunction, calcineurin inhibitor use, and…
  • 2020 American Transplant Congress

    Kidney Transplant Results Comparing Two Formulations of Prolonged-Release Tacrolimus: Paired Study of Kidney Donors

    V. Lopez Jimenez, J. Alonso Titos, J. Gamez España, M. Cabello Díaz, D. Hernández Marrero

    Nephrology Department, Regional University Hospital, University of Malaga, IBIMA, REDinREN (RD16/0009/0006), Málaga, Spain

    *Purpose: Although the formulations of prolonged-release tacrolimus (Advagraf® and Envarsus®) are effective after kidney transplantation in terms of efficacy and safety, no paired analysis has…
  • 2020 American Transplant Congress

    Role of Tacrolimus Dose Adjustment at Discontinuation of Fluconazole in Liver Transplant

    J. Yau, H. Morris

    University of Virginia Health System, Charlottesville, VA

    *Purpose: The purpose of this study was to characterize the effects of fluconazole (fluc) discontinuation on tacrolimus (tac) levels and the role of prophylactic dose…
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

This site uses cookies: Find out more.